Scailyte AG

Scailyte develops artificial intelligence technology for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into diseases by uncovering human's hidden "single-cell"​ secrets. Our AI-based software ScaiVision, offers best-in-class performance for supervised pattern recognition analysis of single-cell data. The performance and clinically-relevant application of the deep learning algorithm has been demonstrated in a scientific publication by our co-founder Prof. Claassen (ETH Zurich). ScaiVision will allow our customers to reduce data analysis time and costs, while increasing groundbreaking insights